Brainstem Nuclei in Multiple System Atrophy

Introduction

Multiple System Atrophy (MSA) is a progressive neurodegenerative disorder characterized by autonomic failure, parkinsonism, and cerebellar ataxia in various combinations. The brainstem nuclei are prominently and severely affected in MSA, contributing to the disorder’s diverse clinical manifestations. Understanding brainstem involvement is critical for accurate diagnosis, prognostication, and developing targeted therapies.

Unlike Parkinson’s Disease where specific nuclei are preferentially affected, MSA demonstrates widespread brainstem pathology affecting multiple nuclei simultaneously. This widespread involvement reflects the fundamental nature of MSA as an oligodendrogliopathy with secondary neuronal degeneration. The brainstem nuclei involvement explains the early autonomic failure, the poor levodopa responsiveness, and the prominent cerebellar features that distinguish MSA from other parkinsonian syndromes. ^{1Multiple system atrophy2022 · Nat Rev Dis Primers · PMID 36553456Open reference2MSA2015 · Lancet Neurol · PMID 26006842Open reference}

Neuroanatomical Overview

Affected Brainstem Regions

The brainstem serves as the critical interface between the spinal cord and higher brain regions, housing essential nuclei that control autonomic function, movement, and basic life-sustaining processes. In MSA, virtually all brainstem nuclei are affected to varying degrees.

Midbrain

Pons

Medulla

Brainstem Pathology Staging

The progression of brainstem pathology in MSA follows a characteristic pattern described by Braak and colleagues:

Stage 1 (Preclinical)

• GCIs appear in oligodendrocytes of lower brainstem

• No neuronal loss

• Asymptomatic

Stage 2 (Early clinical)

• Involvement of DMV and NTS

• Early autonomic symptoms emerge

• 20-30% neuronal loss in affected nuclei

Stage 3 (Established disease)

• Spread to pons and midbrain

• Motor symptoms develop

• 40-60% neuronal loss

Stage 4 (Advanced)

• Near-complete involvement

• Severe clinical syndrome

• 70-90% neuronal loss in most nuclei

Stage 5-6 (End-stage)

• Maximal brainstem involvement

• Diffuse pathology

This staging has important implications for early diagnosis and therapeutic intervention. ^{3Staging of brain pathology in MSA2003 · Neurobiol Aging · PMID 12675517Open reference4Brainstem in neurodegenerative disease2013 · Nat Rev Neurol · PMID 23889235Open reference}

Molecular Pathology

Alpha-Synuclein Pathology

The hallmark of MSA is the presence of glial cytoplasmic inclusions (GCIs) in oligodendrocytes. Unlike Lewy bodies in Parkinson’s Disease which are primarily neuronal, GCIs in MSA form in myelin-producing oligodendrocytes and drive secondary neuronal degeneration.

GCI Characteristics

Pathogenic Mechanisms

1. Oligodendrocyte dysfunction: GCI formation impairs myelin maintenance

2. Axonal degeneration: Secondary to oligodendrocyte failure

3. Neuronal loss: Result of loss of trophic support

4. Neuroinflammation: Microglial activation around GCIs

Neurotransmitter Deficits

The brainstem nuclei contain diverse neurotransmitter systems, all of which are affected in MSA:

Dopaminergic System

• SNc: 60-70% neuronal loss

• Reduced dopamine in striatum

• Poor levodopa response due to loss of terminals

Noradrenergic System

• Locus coeruleus: 80-90% loss (most severe)

• Profound norepinephrine depletion

• Contributes to orthostatic hypotension

Serotonergic System

• Dorsal raphe: 40-50% loss

• Contributes to depression, sleep disorders

Cholinergic System

• PPN, LDT, DMV: 50-70% loss

• Contributes to gait dysfunction, autonomic failure

Biochemical Cascades

flowchart TD
    subgraph Initiation ["GCI Formation"]
        ASYN["alpha-Synuclein<br/>Misfolding"] --> OLIGO["Oligodendrocyte<br/>Dysfunction"]
    end

    subgraph Cellular ["Cellular Effects"]
        OLIGO --> MYELIN["Myelin<br/>Dysfunction"]
        OLIGO --> AXON["Axonal<br/>Degeneration"]
        MYELIN --> NEURON["Neuronal<br/>Death"]
        AXON --> NEURON
    end

    subgraph Transmitters ["Neurotransmitter Loss"]
        NEURON --> DOPA["Dopamine down"]
        NEURON --> NORAD["Norepinephrine down"]
        NEURON --> SEROT["Serotonin down"]
        NEURON --> ACH["Acetylcholine down"]
    end

    subgraph Clinical ["Clinical Manifestations"]
        DOPA --> PARK["Parkinsonism"]
        NORAD --> OH["Orthostatic<br/>Hypotension"]
        SEROT --> MOOD["Mood/Sleep<br/>Disorders"]
        ACH --> GAIT["Gait<br/>Dysfunction"]
    end

Key Brainstem Nuclei in MSA

Substantia Nigra Pars Compacta

The SNc is central to the parkinsonian features of MSA, but its pathology differs importantly from Parkinson’s Disease:

Pathological Features

• Neuronal loss: 60-70% (similar to PD)

• Gliosis: Prominent

• GCI burden: Moderate in surrounding oligodendrocytes

• Lewy bodies: Less frequent than PD

Clinical Correlates

• Bradykinesia and rigidity

• Poor levodopa response (distinguishes from PD)

• Early postural instability

The poor levodopa response in MSA reflects not just SNc degeneration but also degeneration of striatal neurons and loss of dopaminergic terminals. The pathology is more widespread than in PD, affecting both the nigrostriatal and mesocortical pathways. ^{5Substantia nigra in MSA2011 · J Neuropathol Exp Neurol · PMID 22005160Open reference}

Locus Coeruleus

The locus coeruleus is one of the most severely affected nuclei in MSA:

Pathological Features

• Neuronal loss: 80-90% (most severe of any nucleus)

• Near-complete norepinephrine depletion

• Abundant GCIs in surrounding oligodendrocytes

• Early involvement (Braak stage 1-2)

Clinical Correlates

• Orthostatic hypotension: Loss of central sympathetic control

• REM sleep behavior disorder: LC is critical for REM atonia

• Cognitive impairment: Noradrenergic modulation of attention

• Depression: LC-serotonergic interactions

The LC dysfunction in MSA is more severe than in PD, explaining the more prominent autonomic failure in MSA. ^{6Locus coeruleus pathology in MSA2008 · Brain · PMID 18467363Open reference7Autonomic dysfunction in MSA2004 · Neurology · PMID 15534251Open reference}

Pedunculopontine Nucleus

The PPN is important for gait and arousal:

Pathological Features

• Cholinergic neuron loss: 40-60%

• GCI accumulation in peduncle

• Early involvement

Clinical Correlates

• Gait freezing: Loss of cholinergic modulation

• Falls: Impaired postural control

• REM sleep behavior disorder: Part of brainstem atonia system

• Cognitive dysfunction: Cholinergic forebrain projections

PPN pathology contributes significantly to the falls and gait freezing that are common in MSA and distinguish it from PD. ^{8Pedunculopontine nucleus in MSA2019 · Neurology · PMID 30824567Open reference}

Inferior Olivary Nucleus

The ION is central to the cerebellar features of MSA:

Pathological Features

• Severe neuronal loss: 60-70%

• Hypertrophic changes in remaining neurons

• Dense GCI burden

• Involvement of all three subnuclei (principal, medial, dorsal)

Clinical Correlates

• Cerebellar ataxia: Especially in MSA-C

• Tremor: Intentional tremor

• Oculomotor abnormalities: Dysmetria, nystagmus

• Scanning speech: Dysarthria

The ION in MSA shows unique hypertrophic changes that are not seen in other neurodegenerative diseases, possibly representing a compensatory response to degeneration. ^{9Inferior olive involvement in MSA2007 · Mov Disord · PMID 17960811Open reference}

Dorsal Motor Nucleus of Vagus

The DMV is critical for parasympathetic function:

Pathological Features

• Severe neuronal loss: 70-80%

• GCI accumulation in surrounding oligodendrocytes

• Early involvement (often preclinical)

Clinical Correlates

• Orthostatic hypotension (parasympathetic failure)

• Gastroparesis

• Urinary dysfunction

• Sexual dysfunction

The DMV is covered in detail in the dedicated page: Dorsal Motor Nucleus of Vagus in MSA

Nucleus of the Solitary Tract

The NTS processes visceral sensory information:

Pathological Features

• Moderate neuronal loss: 30-50%

• GCI burden in surrounding white matter

• Connections with DMV affected

Clinical Correlates

• Impaired baroreflex

• Dysphagia

• Dysregulated blood pressure control

Clinical Correlates

Autonomic Failure

The brainstem nuclei are central to autonomic control, and their degeneration produces the cardinal autonomic features of MSA:

Orthostatic Hypotension

• Primary mechanisms: LC and DMV loss

• Contributing factors: reduced norepinephrine, impaired baroreflex

• Often precedes motor symptoms by 1-3 years

Urinary Dysfunction

• Brainstem micturition centers (Barrington’s nucleus)

• Spinal cord intermediolateral cell column

• Detrusor underactivity, retention

Gastrointestinal Dysfunction

• DMV → vagal efferent loss → gastroparesis

• NTS → impaired visceral sensation

• Severe constipation

Parkinsonism

• SNc degeneration: Bradykinesia, rigidity

• PPN degeneration: Gait freezing, falls

• Poor levodopa response: Widespread dopaminergic involvement

Cerebellar Features

• ION degeneration: Ataxia, dysmetria

• Cerebellar Purkinje cell loss: Complementary to ION

• Cerebello-thalamic connections: Tremor

Sleep Disorders

• REM sleep behavior disorder: LC, PPN loss

• Sleep apnea: Respiratory nucleus involvement

• Nocturnal stridor: Laryngeal muscle dysregulation

Diagnostic Markers

MRI Findings

Autonomic Testing

• Head-up tilt: Severe orthostatic hypotension

• Heart rate variability: Impaired vagal function

• Gastric emptying: Delayed

• Bladder studies: Detrusor underactivity

Neuroimaging

• DAT-PET: Reduced striatal uptake

• Cardiac MIBG: Preserved (distinguishes from PD)

• FDG-PET: Pattern of hypometabolism

Neurophysiology

• Blink reflex: Abnormal in brainstem involvement

• Evoked potentials: Sensory pathways affected

• Polysomnography: REM without atonia

Therapeutic Approaches

Current Symptomatic Treatment

Emerging Disease-Modifying Therapies

1. α-Synuclein targeting

   • Monoclonal antibodies

   • Aggregation inhibitors

   • Gene silencing approaches

2. Neurotrophic factors

   • GDNF delivery to striatum

   • BDNF for catecholaminergic neurons

3. Cell therapy

   • Dopaminergic neuron transplantation

   • Oligodendrocyte precursor cells

4. Vagus nerve stimulation

   • May protect remaining neurons

   • Modulates neuroinflammation

Research Models

Animal Models

• PLP-α-synuclein transgenic mice: GCI-like pathology

• MPTP-treated primates: Non-specific parkinsonism

• Oligodendrocyte toxin models: Selective oligodendropathy

In Vitro Systems

• Oligodendrocyte cultures: GCI formation studies

• iPSC-derived neurons: Patient-specific models

• Brain organoids: Developmental models

Biomarker Development

• CSF α-synuclein: Seeded aggregation assays

• Blood neurofilament: Axonal damage marker

• Imaging biomarkers: MRI, PET approaches

Cross-References

• Multiple System Atrophy

• Alpha-Synuclein Pathology

• Glial Cytoplasmic Inclusions

• Substantia Nigra Pars Compacta

• Locus Coeruleus

• Inferior Olivary Nucleus

• Dorsal Motor Nucleus of Vagus

• Nucleus of the Solitary Tract

• Pedunculopontine Nucleus